Vitafoods Europe 2024: Bioiberica reveals latest Dermial and Collavant n2 clinical findings
05 Jun 2024 | Bioiberica
We spoke with Daniel Martínez Puig, Bioiberica’s head of R&D human and animal health, and Antonio Vendrell, the company’s marketing and communications director, about the latest clinical study results for Bioiberica’s undenatured type II collagen offering, Collavant n2, and its hyaluronic acid matrix ingredient, Dermial. Watch as we discuss these findings and their implications for the industry.
Upcoming webinars

From boosters to companions: GLP-1 in Food, Beverages and Supplements
Rousselot

Aging Is Inevitable. Longevity Is Negotiable
Sabinsa

Texture challenges in high protein bars: Understanding the benefits of casein
Lactalis Ingredients















